Page last updated: 2024-11-11

1,2-diarachidonoyl-glycero-3-phosphocholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

1,2-diarachidonoyl-glycero-3-phosphocholine: RN given refers to (all-Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine in which the phosphatidyl acyl groups at positions 1 and 2 are both arachidonoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24779076
CHEBI ID60657
SCHEMBL ID235399
MeSH IDM0130658

Synonyms (37)

Synonym
dapc
1,2-diarachidonylphosphatidylcholine
l-diarachidonoyl lecithin
1,2-di-(5z,8z,11z,14z-eicosatetraenoyl)-sn-glycero-3-phosphocholine
LMGP01011052
pc(20:4/20:4)
1,2-diarachidonyl-l-alpha-glycerophosphorylcholine
arachidonin, 1,2-di, dihydrogen phosphate, monoester with choline hydroxide, inner salt, l-
diarachidonoylphosphatidylcholine
choline, hydroxide, dihydrogen phosphate, inner salt, ester with 1,2-diarachidonin, l-
diarachidonyl phosphatidylcholine
pc(20:4(5z,8z,11z,14z)/20:4(5z,8z,11z,14z))
diarachidonyl lecithin
1,2-diarachidonoyl-sn-glycero-3-phosphocholine
1,2-di-o-arachidonoyl-sn-glycero-3-phosphocholine
(7r,14z,17z,20z,23z)-4-hydroxy-7-[(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoyloxy]-n,n,n-trimethyl-10-oxo-3,5,9-trioxa-4-phosphanonacosa-14,17,20,23-tetraen-1-aminium 4-oxide
CHEBI:60657 ,
1,2-diarachidonoyl-glycero-3-phosphocholine
1,2-diarachidyl-3-phosphatidylcholine
17688-29-8
SCHEMBL235399
20:4 (cis) pc
LZLVZIFMYXDKCN-QJWFYWCHSA-N
3,5,9-trioxa-4-phosphanonacosa-14,17,20,23-tetraen-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxo-5,8,11,14-eicosatetraenyl)oxy]-, inner salt, 4-oxide, [r-(all-z)]-
pc(20:4n6/20:4n6)
phosphatidylcholine(20:4n6/20:4n6)
gpcho(20:4w6/20:4w6)
gpcho(20:4n6/20:4n6)
phosphatidylcholine(20:4w6/20:4w6)
pc(20:4w6/20:4w6)
1,2-diarachidonoyl-rac-glycero-3-phosphocholine
(2-{[(2r)-2,3-bis[(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoyloxy]propyl phosphonato]oxy}ethyl)trimethylazanium
Q27104877
l-a-lecithin-diarachidonoyl
diarachidonoyl phosphatidylcholine
DTXSID801297385
PD053621
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,2-diacyl-sn-glycero-3-phosphocholineThe conjugate base of a 1,2-diacyl-sn-glycero-3-phosphocholine compound formed by deprotonation of the phosphate OH group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Lysolipid Incorporation into ER PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))1023
Lysolipid incorporation into Mitochondria PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))514
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))617

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (25.00)18.7374
1990's5 (17.86)18.2507
2000's6 (21.43)29.6817
2010's10 (35.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]